India, April 30 -- The Nuffield Department of Women's & Reproductive Health at the University of Oxford, in collaboration with Serac Healthcare, has published Phase 2 results in The Lancet Obstetrics and Gynaecology, highlighting the potential of a novel molecular imaging agent, 99mTc-maraciclatide, as a non-invasive tool for diagnosing and monitoring Endometriosis.
The technique combines specialized CT imaging with a molecular tracer to identify early signs of the disease, which are often missed by conventional scans. A SPECT-CT scan then reveals where the tracer accumulates, producing detailed images of inflamed tissue and lesions.
The Detect trial enrolled 20 women, 17 of whom underwent laparoscopy following a SPECT-CT scan. Nineteen p...